Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy
COVID-19, the novel coronavirus pandemic, has already spread around the globe affecting more than 18 million people. As previously observed with other coronaviruses, SARS-CoV-2 deeply dysregulate the immune system eliciting respiratory failure and a state of systemic hyperinflammation in severely il...
Uloženo v:
| Vydáno v: | Respiratory medicine Ročník 175; s. 106204 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
01.12.2020
|
| Témata: | |
| ISSN: | 1532-3064, 1532-3064 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | COVID-19, the novel coronavirus pandemic, has already spread around the globe affecting more than 18 million people. As previously observed with other coronaviruses, SARS-CoV-2 deeply dysregulate the immune system eliciting respiratory failure and a state of systemic hyperinflammation in severely ill individuals. Immunotherapy is often used to downgrade the detrimental effects of the disease sustained by high-level of cytokines. Those treatments, however, are known to undermine patients' ability to contain tuberculosis (TB) infection. This study aims to describe interferon-γ release assay (IGRA) results in severe COVID-19 patients eligible for immunosuppressive treatment. Aggregate data were gathered from five hospitals in Milan, Italy, from March 1 to May 15, 2020 and retrospectively analyses. Results were summarized using absolute frequencies and percentages and compared using a two-sided Chi-squared test. Overall, 462 COVID-19 patients were eligible for immunosuppressive therapy, among which 335 were tested using IGRA testing. More than one-third of them (122/335; 36.4%) had an indeterminate IGRA result because of insufficient immune response to mitogen control, 19 (5.7%) tested positive and 194 (57.9) negative. The majority of patients with lymphocytopenia (i.e., total lymphocyte count [TLC] below 1000 cells/mm
) had indeterminate IGRAs (81/155; 52.3%). The proportion becomes even higher in patients with severe lymphocytopenia (i.e., TLC<500 cells/mm
) (36/57; 63%). Our results suggest a possible negative impact of COVID-19 related immune dysregulation on TB infection assessment and management. Close monitoring of individuals with or without retesting of individuals with indeterminate IGRAs and further basic science investigations should to be sought to better comprehend their implication on TB epidemiology. |
|---|---|
| AbstractList | COVID-19, the novel coronavirus pandemic, has already spread around the globe affecting more than 18 million people. As previously observed with other coronaviruses, SARS-CoV-2 deeply dysregulate the immune system eliciting respiratory failure and a state of systemic hyperinflammation in severely ill individuals. Immunotherapy is often used to downgrade the detrimental effects of the disease sustained by high-level of cytokines. Those treatments, however, are known to undermine patients' ability to contain tuberculosis (TB) infection. This study aims to describe interferon-γ release assay (IGRA) results in severe COVID-19 patients eligible for immunosuppressive treatment. Aggregate data were gathered from five hospitals in Milan, Italy, from March 1 to May 15, 2020 and retrospectively analyses. Results were summarized using absolute frequencies and percentages and compared using a two-sided Chi-squared test. Overall, 462 COVID-19 patients were eligible for immunosuppressive therapy, among which 335 were tested using IGRA testing. More than one-third of them (122/335; 36.4%) had an indeterminate IGRA result because of insufficient immune response to mitogen control, 19 (5.7%) tested positive and 194 (57.9) negative. The majority of patients with lymphocytopenia (i.e., total lymphocyte count [TLC] below 1000 cells/mm3) had indeterminate IGRAs (81/155; 52.3%). The proportion becomes even higher in patients with severe lymphocytopenia (i.e., TLC<500 cells/mm3) (36/57; 63%). Our results suggest a possible negative impact of COVID-19 related immune dysregulation on TB infection assessment and management. Close monitoring of individuals with or without retesting of individuals with indeterminate IGRAs and further basic science investigations should to be sought to better comprehend their implication on TB epidemiology.COVID-19, the novel coronavirus pandemic, has already spread around the globe affecting more than 18 million people. As previously observed with other coronaviruses, SARS-CoV-2 deeply dysregulate the immune system eliciting respiratory failure and a state of systemic hyperinflammation in severely ill individuals. Immunotherapy is often used to downgrade the detrimental effects of the disease sustained by high-level of cytokines. Those treatments, however, are known to undermine patients' ability to contain tuberculosis (TB) infection. This study aims to describe interferon-γ release assay (IGRA) results in severe COVID-19 patients eligible for immunosuppressive treatment. Aggregate data were gathered from five hospitals in Milan, Italy, from March 1 to May 15, 2020 and retrospectively analyses. Results were summarized using absolute frequencies and percentages and compared using a two-sided Chi-squared test. Overall, 462 COVID-19 patients were eligible for immunosuppressive therapy, among which 335 were tested using IGRA testing. More than one-third of them (122/335; 36.4%) had an indeterminate IGRA result because of insufficient immune response to mitogen control, 19 (5.7%) tested positive and 194 (57.9) negative. The majority of patients with lymphocytopenia (i.e., total lymphocyte count [TLC] below 1000 cells/mm3) had indeterminate IGRAs (81/155; 52.3%). The proportion becomes even higher in patients with severe lymphocytopenia (i.e., TLC<500 cells/mm3) (36/57; 63%). Our results suggest a possible negative impact of COVID-19 related immune dysregulation on TB infection assessment and management. Close monitoring of individuals with or without retesting of individuals with indeterminate IGRAs and further basic science investigations should to be sought to better comprehend their implication on TB epidemiology. COVID-19, the novel coronavirus pandemic, has already spread around the globe affecting more than 18 million people. As previously observed with other coronaviruses, SARS-CoV-2 deeply dysregulate the immune system eliciting respiratory failure and a state of systemic hyperinflammation in severely ill individuals. Immunotherapy is often used to downgrade the detrimental effects of the disease sustained by high-level of cytokines. Those treatments, however, are known to undermine patients' ability to contain tuberculosis (TB) infection. This study aims to describe interferon-γ release assay (IGRA) results in severe COVID-19 patients eligible for immunosuppressive treatment. Aggregate data were gathered from five hospitals in Milan, Italy, from March 1 to May 15, 2020 and retrospectively analyses. Results were summarized using absolute frequencies and percentages and compared using a two-sided Chi-squared test. Overall, 462 COVID-19 patients were eligible for immunosuppressive therapy, among which 335 were tested using IGRA testing. More than one-third of them (122/335; 36.4%) had an indeterminate IGRA result because of insufficient immune response to mitogen control, 19 (5.7%) tested positive and 194 (57.9) negative. The majority of patients with lymphocytopenia (i.e., total lymphocyte count [TLC] below 1000 cells/mm ) had indeterminate IGRAs (81/155; 52.3%). The proportion becomes even higher in patients with severe lymphocytopenia (i.e., TLC<500 cells/mm ) (36/57; 63%). Our results suggest a possible negative impact of COVID-19 related immune dysregulation on TB infection assessment and management. Close monitoring of individuals with or without retesting of individuals with indeterminate IGRAs and further basic science investigations should to be sought to better comprehend their implication on TB epidemiology. |
| Author | Grisolia, Antonella Castellotti, Paola Francesca Mangioni, Davide Cirillo, Daniela Maria Santus, Pierachille Aliberti, Stefano Torre, Alessandro Rossotti, Roberto Besozzi, Giorgio Marchetti, Giulia Villa, Simone Codecasa, Luigi Ruffo |
| Author_xml | – sequence: 1 givenname: Alessandro surname: Torre fullname: Torre, Alessandro organization: III Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy – sequence: 2 givenname: Stefano surname: Aliberti fullname: Aliberti, Stefano organization: Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy – sequence: 3 givenname: Paola Francesca surname: Castellotti fullname: Castellotti, Paola Francesca organization: Regional TB Reference Centre and Laboratory, Villa Marelli Institute/ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Stop TB Italia ONLUS, Milan, Italy – sequence: 4 givenname: Daniela Maria surname: Cirillo fullname: Cirillo, Daniela Maria organization: Stop TB Italia ONLUS, Milan, Italy; Emerging Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy – sequence: 5 givenname: Antonella surname: Grisolia fullname: Grisolia, Antonella organization: I Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy – sequence: 6 givenname: Davide surname: Mangioni fullname: Mangioni, Davide organization: Infectious Disease Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 7 givenname: Giulia surname: Marchetti fullname: Marchetti, Giulia organization: Clinic of Infectious and Tropical Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, Milan, Italy – sequence: 8 givenname: Roberto surname: Rossotti fullname: Rossotti, Roberto organization: Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy – sequence: 9 givenname: Pierachille surname: Santus fullname: Santus, Pierachille organization: Department of Biomedical and Clinical Sciences (DIBIC), Università Degli Studi di Milano, Milan, Italy; Division of Respiratory Diseases, "L. Sacco" University Hospital, ASST Fatebenefratelli-Sacco, Milan, Italy – sequence: 10 givenname: Giorgio surname: Besozzi fullname: Besozzi, Giorgio organization: Stop TB Italia ONLUS, Milan, Italy – sequence: 11 givenname: Simone surname: Villa fullname: Villa, Simone email: simone.villa@unimi.it organization: Stop TB Italia ONLUS, Milan, Italy; Centre for Multidisciplinary Research in Health Science, Università Degli Studi di Milano, Milan, Italy. Electronic address: simone.villa@unimi.it – sequence: 12 givenname: Luigi Ruffo surname: Codecasa fullname: Codecasa, Luigi Ruffo organization: Regional TB Reference Centre and Laboratory, Villa Marelli Institute/ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; Stop TB Italia ONLUS, Milan, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33186846$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtPwzAQhC1UBC3wBzggH7mkrB9142MpUCpVAqHCNXLcDRglTrCToh7554SXxGlnV9-ONDMiA197JOSUwZgBUxev41DhZsyBfx0UB7lHhmwieCJAycE_fUhGMb4CgJYSDsihECxVqVRD8nEfsHSV8ybsaJ1HDFvTutpHWnu6XDzMaIuxdf6ZFnWg60vqfIH2i-gVbXoWfRvpu2tfaMQtBqTzu6flVcI07Y2fXV7i96urqs7XsWuagDG6LdL2BYNpdsdkvzBlxJPfeUQeb67X89tkdbdYzmerxE6EbBMhUwSuNbNso6fcTDZKWiv0JE-VBasYAuRiahii0bbgXMMGpQYLRvRLwY_I-Y9vE-q3rg-VVS5aLEvjse5ixqWCqRIpyB49-0W7vG84a4Kr-n6yv9r4J86zc0k |
| CitedBy_id | crossref_primary_10_5588_ijtldopen_24_0180 crossref_primary_10_1016_j_imbio_2023_152755 crossref_primary_10_1016_j_ijtb_2023_04_014 crossref_primary_10_1016_j_ijtb_2024_04_005 crossref_primary_10_1128_spectrum_01858_22 crossref_primary_10_1128_JCM_00603_21 crossref_primary_10_1371_journal_pone_0326615 crossref_primary_10_3390_jcm10050918 crossref_primary_10_3390_life12020244 crossref_primary_10_1002_jmv_70058 crossref_primary_10_1016_j_jinf_2021_07_029 crossref_primary_10_1002_hsr2_1695 crossref_primary_10_1128_JCM_01414_21 crossref_primary_10_1371_journal_pgph_0004372 crossref_primary_10_1155_2021_1989277 crossref_primary_10_1016_j_mmifmc_2022_12_003 |
| ContentType | Journal Article |
| Contributor | Gramegna, Andrea Ferrarese, Maurizio Muscatello, Antonio Piscaglia, Marco Bandera, Alessandra Passerini, Matteo Campisi, Daniela Mantero, Marco Schiuma, Marco Lombardi, Alessandra Blasi, Francesco Mancon, Alessandro Saporiti, Matteo |
| Contributor_xml | – sequence: 1 givenname: Alessandra surname: Bandera fullname: Bandera, Alessandra organization: Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Centre for Multidisciplinary Research in Health Science, University of Milan, Milan, Italy; Infectious Disease Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 2 givenname: Francesco surname: Blasi fullname: Blasi, Francesco organization: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 3 givenname: Daniela surname: Campisi fullname: Campisi, Daniela organization: TB Reference Centre and Laboratory, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy – sequence: 4 givenname: Maurizio surname: Ferrarese fullname: Ferrarese, Maurizio organization: TB Reference Centre and Laboratory, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy – sequence: 5 givenname: Andrea surname: Gramegna fullname: Gramegna, Andrea organization: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 6 givenname: Alessandra surname: Lombardi fullname: Lombardi, Alessandra organization: Laboratory of Clinical Microbiology, Virology and Bioemergency, ASST Fatebenefratelli-Sacco, Milan, Italy – sequence: 7 givenname: Alessandro surname: Mancon fullname: Mancon, Alessandro organization: 1st Division, Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy – sequence: 8 givenname: Marco surname: Mantero fullname: Mantero, Marco organization: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 9 givenname: Antonio surname: Muscatello fullname: Muscatello, Antonio organization: Infectious Disease Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 10 givenname: Matteo surname: Passerini fullname: Passerini, Matteo organization: 1st Division, Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy – sequence: 11 givenname: Marco surname: Piscaglia fullname: Piscaglia, Marco organization: 1st Division, Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy – sequence: 12 givenname: Matteo surname: Saporiti fullname: Saporiti, Matteo organization: TB Reference Centre and Laboratory, Villa Marelli Institute, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy – sequence: 13 givenname: Marco surname: Schiuma fullname: Schiuma, Marco organization: 3rd Division, Department of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy |
| Copyright | Copyright © 2020 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2020 Elsevier Ltd. All rights reserved. |
| CorporateAuthor | Milan TB-COVID-19 study group |
| CorporateAuthor_xml | – name: Milan TB-COVID-19 study group |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.rmed.2020.106204 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-3064 |
| ExternalDocumentID | 33186846 |
| Genre | Journal Article |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29P 3O- 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABOCM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AEXQZ AFCTW AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGRNS AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI ASPBG AVWKF AXJTR AZFZN BKEYQ BKOJK BLXMC BNPGV BNQBC BPHCQ BVXVI CAG CGR COF CS3 CUY CVF DU5 EBS ECM EFJIC EFKBS EIF EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEJ HMK HMO HVGLF HZ~ IHE IXB J1W K-O KOM L7B M29 M41 MO0 N9A NPM O-L O9- OAUVE OI- OK1 OU. OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- RIG ROL RPZ RSU SAE SDF SDG SEL SES SEW SPCBC SSH SSZ SV3 T5K UHS UV1 WH7 WOW WUQ X7M Z5R ZGI ZXP ~G- 7X8 ACLOT EFLBG ~HD |
| ID | FETCH-LOGICAL-c534t-348e02991c1d972a5d64cc395b86c0c61e00b37a1eea9cf2290de490c0a3229f2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 17 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000600971000007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1532-3064 |
| IngestDate | Sun Sep 28 00:46:07 EDT 2025 Mon Jul 21 06:04:45 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 Tuberculosis Tocilizumab Anakinra Cytokine-blocking agents IGRA |
| Language | English |
| License | Copyright © 2020 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c534t-348e02991c1d972a5d64cc395b86c0c61e00b37a1eea9cf2290de490c0a3229f2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://www.resmedjournal.com/article/S0954611120303449/pdf |
| PMID | 33186846 |
| PQID | 2460763804 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2460763804 pubmed_primary_33186846 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-12-01 |
| PublicationDateYYYYMMDD | 2020-12-01 |
| PublicationDate_xml | – month: 12 year: 2020 text: 2020-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Respiratory medicine |
| PublicationTitleAlternate | Respir Med |
| PublicationYear | 2020 |
| SSID | ssj0009440 |
| Score | 2.4275427 |
| Snippet | COVID-19, the novel coronavirus pandemic, has already spread around the globe affecting more than 18 million people. As previously observed with other... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 106204 |
| SubjectTerms | Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 - therapy COVID-19 - virology Female Humans Immunity - physiology Immunosuppression - methods Interferon-gamma Release Tests - methods Interferon-gamma Release Tests - statistics & numerical data Interleukin 1 Receptor Antagonist Protein - therapeutic use Italy - epidemiology Latent Tuberculosis - diagnosis Latent Tuberculosis - epidemiology Latent Tuberculosis - immunology Latent Tuberculosis - prevention & control Lymphopenia - immunology Male Retrospective Studies SARS-CoV-2 - genetics Severity of Illness Index |
| Title | Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33186846 https://www.proquest.com/docview/2460763804 |
| Volume | 175 |
| WOSCitedRecordID | wos000600971000007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC6uMluHnuSWq320FqkSm9hs91IoSQ1aQs9-s-dTbb2JAheQggMhJ3Zec83CN34rvTcQFJCY6oId1RChGKSBJoLkBFtYMTKZRNBtxsOBqJnE26Fbatc6sRSUQ8zZXLkty73IeRmIeV3k09itkaZ6qpdobGOagxcGSPVwWCFFi54NRDpMZcYT9sOzVT9XTlYG4gPXfPBgLL_7mKWpqa1-9-f3EM71snEjUoq9tGaTg_QVseW0Q_RVy_X43KdV77AWfyTmC1wluL202sDTw34RvqBwaXF_Xu8bNlK4Q1bKNYCmxwuBsuqc42bL-_tB-IIXLY4x2Ndko7M9ElWzCZVu-1c42rea3GE3lqP_eYzsbsYiPIYnxLGQ03BdDnKGYoAGDz0uVJMeHHoK6p8R1Mas0A6WkuhEoMiPzTsVlSCyhCJe4w20izVpwhTiN-5p8CrFwn3YwfImOtJFYY6oTwJ6-h6ebgRyLopYMhUZ7MiWh1vHZ1UHIomFShHxJgB_uf-2R-oz9G2YXzVlXKBagncdH2JNtV8Oiryq1KI4Nntdb4BWS7RtQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preliminary+observations+on+IGRA+testing+for+TB+infection+in+patients+with+severe+COVID-19+eligible+for+immunosuppressive+therapy&rft.jtitle=Respiratory+medicine&rft.au=Torre%2C+Alessandro&rft.au=Aliberti%2C+Stefano&rft.au=Castellotti%2C+Paola+Francesca&rft.au=Cirillo%2C+Daniela+Maria&rft.date=2020-12-01&rft.issn=1532-3064&rft.eissn=1532-3064&rft.volume=175&rft.spage=106204&rft_id=info:doi/10.1016%2Fj.rmed.2020.106204&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1532-3064&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1532-3064&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1532-3064&client=summon |